Designing of disruptor molecules to restrain the protein-protein interaction network of VANG1/SCRIB/NOS1AP using

Suchandra Roy Acharyya1, Plaboni Sen1, Thirukumaran Kandasamy1

  • 1Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, 39, India.

Molecular Diversity
|June 1, 2022
PubMed

Insights

Researchers identified novel small molecules, VNS003 and VNS005, to disrupt the VANG1/SCRIB/NOS1AP protein complex, a key player in cell migration and cancer progression. VNS003 shows particular promise as an inhibitor for both the complex and individual proteins.

Area of Science:

  • Computational Biology
  • Drug Discovery
  • Cancer Research

Background:

  • Protein-protein interaction networks are crucial for cell signaling and oncogenic pathways.
  • Dysregulated protein interactions can drive cancer progression, making them key therapeutic targets.
  • The VANG1/SCRIB/NOS1AP protein complex regulates cell migration and is implicated in cancer.

Purpose of the Study:

  • To computationally model and analyze the VANG1/SCRIB/NOS1AP protein interaction network.
  • To identify novel small molecules capable of disrupting this protein complex using fragment-based drug design.
  • To validate the efficacy and stability of potential drug candidates through molecular dynamics simulations.

Main Methods:

  • In-silico modeling and protein-protein docking were used to visualize the VANG1/SCRIB/NOS1AP complex.
  • Fragment-based drug design identified hotspots within the protein complex for small molecule targeting.
  • Pharmacokinetic screening, 2D interaction studies, and 100 ns molecular dynamics simulations validated drug candidates.

Main Results:

  • Four potential small molecular disruptors were identified through rapid screening.
  • Two novel molecules, VNS003 and VNS005, demonstrated stability and disruptive potential against the VANG1/SCRIB/NOS1AP complex.
  • VNS003 was further validated as a potent inhibitor for both the protein assembly and individual protein targets.

Conclusions:

  • Fragment-based drug design is an effective strategy for targeting complex protein-protein interactions.
  • VNS003 and VNS005 represent promising novel therapeutic agents for inhibiting the VANG1/SCRIB/NOS1AP complex.
  • VNS003 is a highly suitable candidate for further development as an anti-cancer therapeutic by disrupting critical protein interactions.

Related Concept Videos

Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.8K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.6K